The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 2, 1998, Pages 93-96

  Sternic, Nadezda ^a   Kacar, Aleksandra ^a   Filipovic, Sasa ^a   Svetel, Marina ^a   Kostic, Vladimir S ^a  

^a Institute of Neurology   (Yugoslavia)

Author keywords

MAO A; Moclobemide; Parkinson's disease

Indexed keywords

LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; HEADACHE; HUMAN; INSOMNIA; NAUSEA; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESSNESS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0031901240     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations in disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders: I. New York: Butterworth Scientific. 1982: 96-122.
2. Kostic VS, Przedborski S, Plaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-5.
3. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH. Chase TN, Wearing-off fluctuations in Parkinson's disease: contribution ofpostsynaptic mechanisms. Ann Neurol 1994;36:27-31.
4. Szelenyi I, ed. Inhibitors of monoamine oxidase B: pharmacology and clinical use in the neurodegenerative disorders. Basel: Birkhauser, 1993.
5. Finberg JPM, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS. Influence of selective inhibition of monoaminc oxidase A and B on striatal metabolism of 1-DOPA in hemiparkinsonian rats. J Neurochem 1995;65:1213-20.
6. Oreland L, Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand 1991;81(suppl 136):60-5.
7. Berry MD, Juorio AV, Paterson IA. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 1994;44:141-61.
8. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-12.
9. Fulton B, Benfield P, Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs 1996;52:450-74.
10. Ward C, Gibb W. Research diagnostic criteria for Parkinson's disease. In: Steifer MB, Korczyn AD, Melamed E, Youdim MBH, eds. Parkinson's disease: anatomy, pathology and therapy. New York: Raven Press, 1990:245-9.
11. Poewe WH, Lees AJ, Stem GM. Clinical and pharmacokinetic observation with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations. Eur Neurol 1987;27(suppl 1): 93-7.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression arid mortality. Neurology 1967;17:427-12.
13. Fahn S, Parkinson's Rating Scale Group. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments In Parkinson's disease, vol 2. Florbam Park: MacMillan, 1987:153-63.
14. AIMS. In: Guy W, ed. ECDEU assessment manual, Rockville, MD: Department of Health, Education and Welfare, 1976:534-7.
15. Folstein MF, Folslein SE, McHugh PR. Mini-mental state examination: a practical method of grading the mental stale of patients for the clinician. J Psychiatr Res 1975;12:189-98.
16. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry 1960;23:56-62.
17. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35: 837-44.
18. Spitzer RL, Endicott J, Robins E, Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-82.
19. Sieradzan K, Channon S, Ramponi C, et al. The therapeutic potential of moclobemide. a reversible selective monoaminc oxidase A inhibitor in Parkinson's disease. J Clin Psychopharmacol 1995;15 (suppl 2):51S-9S.
20. Ruggieri S, Stocchi F, Bramante L, et al. MAO-A inhibitor (moclobemide) has a symptomatic effect in Parkinson's disease. Mov Disord 1994;9(suppl 1):72.
21. Hauser RA, Zesiewicz TA, Factor SA, Gutttnan M, Weiner WJ. Clinical trials of add-on medications in Parkinson's disease: efficacy versus usefulness. Park Rel Disord 1997;3:1-6.
22. Fowler CJ, Wiberg A, Oreland L, et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neurol Transm Park Dis Dement Sect 1980;49:1-20.
23. Bentue-Ferrer D, Menard G, Allain H. Monoamine oxidase B inhibitors. CNS Druga 1996;6:217-36.
24. Lewitt PA, Segel SA, Mistura KL, et al. Symptomatic antiparkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clin Neuropharmacol 1993;16: 332-7.
25. Parkinson Study Group. A controlled trial of lazabemide (RO 19 6327) in untreated Parkinson's disease. Ann Neurol 1993;33:350-6.
26. Palfreyman MG, McDonald IA. Zreika M, et al. MDL 72794 A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease. J Neurol Transm Park Din Deinem Sect 1993;40 (suppl):101-11.
27. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. Br Med J 1995;311:1602-7.